RxDoctor Payments Data

Nicole Spence, NP

Psychiatric/Mental Health · Otterbein, INNPI 1699414599

Payments from drug & device makers

$1,335in general payments, 2019–2025

Across 44 payments — averaging $30.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$896
  • Collegium Pharmaceutical, Inc.$117
  • Alkermes, Inc.$58
  • Noven Therapeutics, LLC$55
  • Ironshore Pharmaceuticals Inc.$51
  • Corium, LLC$40
  • plus $118 from 6 others

What the payments were for

  • Food & beverage$1,335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,335 in reported general payments places this provider in the 65th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$9,720
Medicare patients
26
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl58$83,712
RexultiBrexpiprazole22$29,953
Lurasidone Hcl21$9,551
Lamotrigine ErLamotrigine29$9,344
Aripiprazole70$6,697
Lisdexamfetamine Dimesylate12$3,833
Quetiapine Fumarate ErQuetiapine Fumarate23$1,220
Atomoxetine Hcl15$1,191
Bupropion XlBupropion Hcl82$1,185
Lamotrigine121$1,128
Buspirone Hcl66$750
Duloxetine Hcl49$665
Doxepin Hcl23$434
Venlafaxine Hcl ErVenlafaxine Hcl40$381
Hydroxyzine Hcl26$358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$896$83,71258 claims
Otsuka America Pharmaceutical, Inc.Rexulti$15$29,95322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Otterbein

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →